Google
JBIO — JADE BIOSCIENCES, INC. (Healthcare >> Biotechnology)
JBIO FAQ
What is JBIO's ROE?
JADE BIOSCIENCES, INC. reports a Return on Equity (ROE) of -43.72%.
What is JBIO's dividend yield?
JADE BIOSCIENCES, INC. offers a dividend yield of 0.00%.
What is JBIO's Deepscope Quality Score?
Deepscope rates JBIO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy JBIO?
Deepscope's AI Timing Score for JBIO is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does JBIO belong to?
JADE BIOSCIENCES, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 15.26
Price
0.04
(0.26%)
Day Change
|
|
|---|
JBIO, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 15.26 |
| PBV / Sector |
3.12 / 4.79
|
| Earning Per Share | -2.14 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
19.01 M
GREAT
|
| Average 1W Daily Value |
34.08 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
37% |
| Registration Details |
| Analyze Date | 2026-06-11 09:55:10 |
| Symbol | JBIO |
| Name | JADE BIOSCIENCES, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 60.86 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 926.29 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building 23, Waltham, MA, United States, 02453
Phone: 781 312 3013
Website: https://jadebiosciences.com
Employees: 55
Sector: Healthcare >> Biotechnology
Description: Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
